Merus Stock Price, News & Analysis

Merus N.V. (Nasdaq: MRUS) presented clinical data on MCLA-145 at the virtual ESMO Immuno-Oncology Congress 2021. The phase 1 trial, involving 34 patients with solid tumors, showed preliminary evidence of antitumor activity, especially at doses ≥25 mg biweekly. Patients were treated at eight dose levels with a median age of 60.5 years. While treatment-related adverse events occurred in 67.6% of patients, robust T-cell activation was recorded. The trial aims to refine the maximum tolerated dose and evaluate efficacy in PD-L1+ tumors.

Merus N.V. (MRUS) announced interim data from the phase 1/2 trial of its bispecific antibody MCLA-145, targeting CD137 and PD-L1 in solid tumors, as of July 14, 2021. This data will be presented at the ESMO Immuno-Oncology Congress 2021 from December 8-11, 2021. The ongoing trial includes a dose escalation phase followed by planned expansion, marking MCLA-145 as a key candidate co-developed with Incyte. Merus retains commercialization rights in the U.S. and aims to leverage its innovative Bispecific platform for enhanced cancer treatment.

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, has announced that CEO Bill Lundberg, M.D., will participate in a fireside chat at the Jefferies London Healthcare Conference. This virtual event is scheduled for November 18, 2021, and the prerecorded session will be available on the Company's investor webpage at 8:00 am GMT/3:00 am ET. Merus is known for developing innovative multispecific antibody therapeutics, Biclonics and Triclonics, which show potential advantages similar to conventional human monoclonal antibodies.

Merus N.V. (Nasdaq: MRUS) announced the pricing of a public offering of 3,859,650 common shares at $28.50 per share, generating approximately $110.0 million in gross proceeds. The offering, set to close on or about November 9, 2021, includes an option for underwriters to purchase an additional 578,947 shares. The funds will be utilized for advancing clinical development, preclinical research, and general corporate purposes. Jefferies LLC and SVB Leerink LLC are the joint book-running managers for the offering.

Merus N.V. (Nasdaq: MRUS) has announced a proposed underwritten public offering of its common shares to advance its clinical development of innovative bispecific and trispecific antibodies. The offering includes an additional 30-day option for underwriters to purchase 15% more shares. Proceeds will fund clinical and preclinical research, technology development, and working capital. Jefferies LLC and SVB Leerink LLC are the joint managers for this offering, which is contingent on market conditions. The offering follows a previously filed shelf registration statement with the SEC.

Merus N.V. (Nasdaq: MRUS) announced positive developments regarding its zenocutuzumab (Zeno) program after a Type B meeting with the FDA, securing alignment on a potential tumor-agnostic indication. The company shared interim clinical results for its MCLA-158 program at the AACR-NCI-EORTC Conference, with three of seven advanced head and neck cancer patients showing partial responses. Financially, the company reported collaboration revenue of $13.7 million for Q3 2021, up from $8.6 million a year prior, although operating expenses rose significantly. Cash reserves are projected to fund operations into H2 2024.

Merus, a clinical-stage oncology company, presented promising clinical data for its MCLA-158 treatment for advanced head and neck squamous cell carcinoma (HNSCC) during the AACR-NCI-EORTC conference. Out of 10 patients, 3 achieved partial responses and 1 a complete response. In preclinical studies, the Zeno antibody demonstrated a potent ability to block cancer cell growth. The safety profile for MCLA-158 showed infusion reactions as the most common adverse event. Future updates on the MCLA-158 trial are planned for 2022, indicating potential for further therapeutic advancements.

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced two poster presentations scheduled for the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. The presentations focus on:

• Zenocutuzumab: Targeting HER2/HER3 in cancers with NRG1 fusions.
• MCLA-158: Evaluating antitumor activity in advanced head and neck squamous cell carcinoma.

The posters will be available on demand throughout the conference and on the company's website.

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced CEO Bill Lundberg's participation in several upcoming investor conferences. Key events include a panel discussion at Citi’s 16th Annual BioPharma Virtual Conference on September 9, 2021, a pre-recorded presentation at H.C. Wainwright 23rd Annual Global Investment Conference available on September 13, and a presentation at the 2021 Cantor Virtual Global Healthcare on September 27, 2021. The webcasts will be accessible on the company's investor page, with archived presentations available for a limited time.